US Oncologist Survey: Optimizing Treatment for Advanced Prostate Cancer


#30859

52pages

Assessment Group

$ 8900

In Stock


Patient case scenarios that progressively unfold, presented to 154 oncologists in a survey for their open-ended responses providing rich insight into their clinical decisions. Data includes specific treatment choices, factors that influence their decisions, barriers to optimal treatment and confidence in treatment and management of patients. This primary research provides the oncology prescribing information that you are missing, directly from high-prescribing US Oncologists on the treatment of patients with advanced prostate cancer. 

Case highlights include:

  • Rising PSA in a patient without documented metastatic disease
  • Asymptomatic castration resistant metastatic disease
  • Symptomatic metastatic disease
  • Symptomatic disease in an elderly patient

Treatment decisions for advanced stages of cancer are difficult to track as information quickly changes along with the introduction of new information and products impacting oncologists’ decisions. This series of reports will allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer. 

This report allows you to:

  • Understand what occurs with actual patients
  • Access the most up-to-date prescribing trends
  • Gain actionable data for developing and improving your market strategies
  • Pinpoint needs of your target audience
  • Focus resources to maximize the effectiveness of your budget
  • Understand where your product fits
  • Understand where your competitor’s product fits
  • Design messages to advance brand performance

Patient case scenarios that progressively unfold, presented to 154 oncologists in a survey for their open-ended responses providing rich insight into their clinical decisions. Data includes specific treatment choices, factors that influence their decisions, barriers to optimal treatment and confidence in treatment and management of patients. This primary research provides the oncology prescribing information that you are missing, directly from high-prescribing US Oncologists on the treatment of patients with advanced prostate cancer.
Table of Contents

Chapter 1: Introduction
Table 1. Treatment Options in Advanced Prostate Cancer

Chapter 2: Respondent Demographics
Table 2.1 Eligibility Criteria for Survey Participation
Figure 2.1 Gender of Survey Respondents
Figure 2.2 Years Since Medical School Graduation
Figure 2.3 Practice Settings
Figure 2.4 Practices in NCI Cancer Centers
Figure 2.5 Geographic Settings
Figure 2.6 Survey Respondents by States
Figure 2.7 Number of Physicians in Practice Groups
Figure 2.8 Minimal Acceptable Level of Evidence in Determining Treatment Regimen

Chapter 3: Treatment of a patient with increased PSA and adenocarcinoma
Next step in a patient with increased PSA and adenocarcinoma
Figure 3.1
Tests to be performed at this time with the patient
Figure 3.2
Confidence in treating to optimal outcome
Figure 3.3
Treatment decision with disease progression
Figure 3.4
Treatment decision with disease progression
Figure 3.5
Factors that influenced treatment
Figure 3.6

Chapter 4: Elderly patient treated for Gleason’s 7 adenocarcinoma, increased PSA 18 months later 23
Barriers to optimal treatment
Figure 4.1
Confidence in treating to optimal outcome
Figure 4.2
Treatment following rising PSA on leuprolide
Figure 4.3
Treatment decision upon disease progression
Figure 4.4
Factors that influenced treatment
Figure 4.5
Factors that influenced treatment by chosen agent
Table 4.1
Other agents that would be appropriate to include in therapy
Figure 4.6
Treatment upon rising PSA
Figure 4.6
Treatment upon further disease progression
Figure 4.7

Chapter 5: Patient with Gleason’s 3+4 adenocarcinoma and multiple metastases to pelvis and spine develops castration-resistant disease.
Appropriate Treatment
Figure 5.1
Confidence in treating to optimal outcome
Figure 5.2
Continuation of LHRH agonist
Figure 5.3
Factors Associated with Continuing LHRH Agonist
Figure 5.4
Cycles of docetaxel that the patient should receive
Figure 5.5
Next therapy with good performance status upon progressing after docetaxel
Figure 5.6

Chapter 6: Elderly patient with Gleason’s 5+5 and multiple metastases
Treatment of patient
Figure 6.1
Confidence in treating to optimal outcome
Figure 6.2
Treatment of patient’s progressive disease
Figure 6.3

Chapter 7: Summary
Appendix A: Survey Instrument